Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study confirms an association between TNF-α antagonist exposure and alopecia, indicating a class effect among the medications examined.

This study concluded that alpha(1)-adrenoceptor antagonists are more effective than finasteride in the short term for reducing symptoms of lower urinary tract symptoms associated with benign prostatic hyperplasia.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.

In this mouse study, the researchers found that the monoclonal antibody ME1 causes hair follicle inflammation by up-regulating TNFα, which can be reduced by TNFα and interleukin-1 inhibitors.

This study found that TNFα inhibitors can induce psoriatic alopecia, highlighting that early diagnosis and discontinuation of the drugs in some cases may prevent irreversible scalp damage.

This study found that IL-1 alpha inhibits the growth of cultured human hair follicles and hair fibers, suggesting a potential role in inflammatory hair loss conditions like alopecia areata.

This study established a stable cell line for CRF1 receptor screening, which can be used to develop functional cosmetics and modulators potentially affecting hair re-growth.

This case report suggests that oral finasteride, used for benign prostatic hyperplasia, may be associated with intraoperative floppy-iris syndrome during cataract surgery.

This literature review identified that phosphodiesterase 5 inhibitors, such as Tadalafil, are highly effective in improving lower urinary tract symptoms associated with benign prostatic hyperplasia, while the efficacy of saw palmetto remains inconsistent.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

This article reviews emerging treatments for androgenetic alopecia, including topical 5-alpha-reductase inhibitors and prostaglandin modulators, but reports no clinical results and calls for further efficacy evidence, especially for PRP.

This review examines the cognitive effects of medications for lower urinary tract symptoms and indicates that muscarinic antagonists, particularly oral oxybutynin, pose the highest risk for cognitive impairment.

This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.

This review discusses medical therapies for benign prostatic hyperplasia, highlighting the importance of personalizing treatments to individual patient needs and preferences.

This article discusses the various roles of steroids in vertebrate organ systems and notes several glucocorticoids that were among the Top 200 Drugs by sales in the 2010s, but it reports no new clinical findings.

The researchers proposed that an epigenetic change in brain androgen receptors caused by finasteride could lead to post finasteride syndrome, while trazodone might reverse this effect by altering the epigenetic expression related to erection and libido.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.

This case report presents the first instance in Korea of unilateral gynecomastia and breast pain associated with doxazosin use.

This review discusses current anti-inflammatory treatment options for calcium pyrophosphate crystal deposition disease (CPPD) and highlights the lack of crystal-targeted therapies, emphasizing the need for more research to guide treatment.

Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.

This quiz based on a Journal of Investigative Dermatology article reports no new clinical results but serves as an educational tool for diagnosing scalp conditions, including scalp psoriasis and psoriatic alopecia.

This review details the adverse effects and drug interactions of biologic agents used in rheumatoid disease treatment, highlighting their significant side effect profile without reporting new clinical findings.

This study found that estrogen receptor beta plays a significant role in murine hair growth control, potentially acting as a silencer of estrogen receptor alpha's catagen-promoting effects.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

This review examines the pharmacological properties and potential clinical benefits of 5α‐reductase inhibition in prostate cancer but reports no new research findings.

This article reviews treatment options for androgenetic alopecia, highlighting potential uses of plant materials, but reports no new clinical results.

This article reviews guidelines and medications for treating benign prostatic hyperplasia but presents no new clinical results.

This review discusses the molecular mechanisms of androgenetic alopecia and evaluates current and potential treatments, highlighting the limitations of minoxidil and finasteride and exploring newer approaches like growth factors and cytokines, topical 5-alpha-reductase inhibitors, and platelet-rich plasma injections as more effective and safer alternatives.

This review examines the molecular mechanisms and current treatment options for androgenetic alopecia, highlighting potential future therapies but providing no new experimental findings.